Navigation Links
BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
Date:7/14/2011

NOVATO, Calif., July 14, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.  A Phase 1/2 trial for BMN 673 for the treatment of patients with solid tumors was initiated in January 2011 and is ongoing.

"We are excited to be at the forefront of studying the potential benefit of PARP inhibitors in hematological malignancies," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin.  "Our approach to the development of our PARP inhibitor is to identify tumor mutations that are more susceptible to treatment with BMN 673 and to target subgroups based on the genetic basis of the disease.  We are committed to the advancement of our pipeline and look forward to many clinical milestones over the next 18 months."

This Phase 1 trial is a two-arm, open-label dose escalation study to determine the maximum tolerated dose and to assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of once daily, oral BMN 673 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).  The study will enroll approximately 80 patients across multiple sites in the U.S. and UK.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin Announces Roll-Out of National PKU Registry
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin Announces Third Quarter 2008 Financial Results
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
9. BioMarin to Present at the Piper Jaffray Healthcare Conference
10. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... SURPRISE, ARIZ. (PRWEB) May 21, 2015 ... E. Webb Medical Center (BDWMC), Sun Health Foundation funded ... medical center’s new inpatient pharmacy with the most up-to-date ... to open June 2. The pharmacy's 45 staff members ... much larger 4,895-square-foot space in the coming days. ...
(Date:5/21/2015)... May 21, 2015 Veolia’s environmental ... exclusive North American distribution agreement with VWR to ... , With more than 160 years of experience, ... services for laboratory and production facilities, has cultivated ... and differentiated services to enable science. Endetec’s ...
(Date:5/20/2015)... , May 20, 2015 Research and Markets ... of the "Top Technologies in HW_Technical Insights" ... of this report evaluated technology trends in the Health ... that are likely to have an impact in the ... analysis of the top 10 health and wellness technologies ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... 2011 Pacific Shore Holdings, Inc. (previously Green Shores, Inc.), ... from the Financial Industry Regulatory Authority ("FINRA") for the change ... about the symbol change, as it takes us one step ... Markets. "Once we enter the Public Marketplace, we believe that ...
... IPSWICH, Mass., Feb. 14, 2011 New England Biolabs has ... ™ and One Taq Hot Start DNA Polymerases. Optimized ... DNA Polymerases, these new products offer robust amplification across a ... The 3´–5´ exonuclease activity of Deep Vent increases the fidelity ...
... Technology Catalysts International (TCI), leading global consultants to the ... in drug delivery have identified parenteral depots as key ... a different pathway for new drug development, and potential ... a crowded pharmaceutical field. In general, biopharmaceuticals ...
Cached Biology Technology:Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA 2New England Biolabs Introduces OneTaq™ DNA Polymerase, a Robust Solution for Routine and Difficult PCR 2Parenteral Depots Offer $8 Billion of Reformulation Opportunities and a Strong Competitive Edge in Crowded Pharmaceutical Space 2
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Synaptics,(Nasdaq: SYNA ), a leading developer ... entertainment devices, today reported,financial results for the first ... reflect the expensing of non-cash share-based,compensation for all ... quarter of fiscal 2009 was $115.9 million, an,increase ...
... induce "synesthetic" experiences where one sense triggers the ... according to a new study in the journal ... for Psychological Society. The findings suggests that ... necessarily have extra connections in their brain; rather, their ...
... The Office of Dietary Supplements (ODS) at the National ... ninth issue of the Annual Bibliography of Significant Advances ... 2007 Bibliography include research supported by government, industry, and ... research covers a wide array of laboratory, human studies, ...
Cached Biology News:Synaptics Reports Record Results for First Quarter of Fiscal 2009 2Synaptics Reports Record Results for First Quarter of Fiscal 2009 3Synaptics Reports Record Results for First Quarter of Fiscal 2009 4Synaptics Reports Record Results for First Quarter of Fiscal 2009 5Synaptics Reports Record Results for First Quarter of Fiscal 2009 6Synaptics Reports Record Results for First Quarter of Fiscal 2009 7Synaptics Reports Record Results for First Quarter of Fiscal 2009 8Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia 2Annual Bibliography of Significant Advances in Dietary Supplement Research 2007 2
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Bag-1 (K-20)...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
Biology Products: